The new corporate law (the Reform) will enter into force on 1 January 2023, putting an end to many years of discussion. The aim of this important reform is to modernize the corporate law. The main changes are the following:More
The European Data Protection Board (hereafter ‘EDPB’) has published Guidelines for the calculation of fines under the General Data Protection Regulation (GDPR). In this part 6 of a series of six articles, we will go through how the supervisory authority must consider that the setting of a fine must always ensure that the fine is effective, proportionate and dissuasive with regard to each specific case. In practice, this means the amount of the fine imposed must be tailored to the infringement committed in its specific context.More
On 1 August 2022, not only the annual national holiday could be celebrated extensively in Switzerland. Particularly noteworthy is also the entry into force of the new requirements for the regulation of medical cannabis.
Cannabis was qualified as a prohibited narcotic in Switzerland until the end of summer 2022 – without further specification in relation to a medical application. Accordingly, the cultivation, importation, production, and marketing of cannabis required an exemption permit from the Federal Office of Public Health (FOPH).More
The European Data Protection Board (hereafter ‘EDPB’) has published Guidelines for the calculation of fines under the General Data Protection Regulation (GDPR). In this part 5 of a series of six articles, we will go through the amount of fines when the turnover is up to €500 million in the previous financial year and more than €500 million in the previous financial year, the notion of “undertaking”, its corporate liability, the Akzo presumption, the determination of the turnover and to whom in an undertaking a fine is addressed.
Just in time for summer, the miniseries «How to Change Your Mind» will be launched in July on the Netflix streaming platform. In this documentary series, author Michael Pollan and Co. analyse the history and applications of psychedelic substances such as LSD, psilocybin, MDMA and mescaline. According to experts, research with psychedelics (also known as hallucinogens) or related substances will increase worldwide in the coming years. The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years. The legal framework regarding the use of psychedelics in patients is very pragmatic in Switzerland and unique internationally. Switzerland is a leader in the research and use of psychedelics in psychiatry and is considered an innovation driver in this field. Nevertheless, the regulatory hurdles for researchers and patients are still extremely high. In this article we elaborate on the requirements under which psychedelics may be used in Switzerland today.
MLL is ‘noted for its very attentive customer contact. It communicates well and gives good, understandable explanations to the client’ and ‘for every question, there are the right people in-house available to perform very good, cost-efficient and timely work’
MLL is ‘highly experienced and professional’ and ‘composed of extremely competent and responsive lawyers, who understand the needs of their clients’
The team is ‘pragmatic, efficient and easy to work with’
MLL is ‘a big law firm with a good reputation’ that ‘provides a consistent level of quality and service’